Aporphine

Last updated
Aporphine
Aporphine.svg
Identifiers
  • 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
Formula C17H17N
Molar mass 235.330 g·mol−1
3D model (JSmol)
  • c12c(cccc1)CC4c3c(cccc23)CCN4C
  • InChI=1S/C17H17N/c1-18-10-9-12-6-4-8-15-14-7-3-2-5-13(14)11-16(18)17(12)15/h2-8,16H,9-11H2,1H3
  • Key:BZKUYNBAFQJRDM-UHFFFAOYSA-N

Aporphine is an alkaloid with the chemical formula C17H17N. It is the core chemical substructure of the aporphine alkaloids, a subclass of quinoline alkaloids. It can exist in either of two enantiomeric forms, (R)-aporphine and (S)-aporphine.

Contents

Derivatives

Many different derivatives of aporphine have been isolated from plants. [1] For example, many water lilies ( Nymphaea species) produce aporphine alkaloids such as nymphaeine, nymphaline, nupharine, α- and β-nupharidine. [2]

In vitro, tests of some aporphine derivatives isolated from Cassytha filiformis , namely, actinodaphnine, cassythine, and dicentrine, showed antiparasitic activity against Trypanosoma brucei . Investigation of possible mechanisms revealed that the compounds bind to DNA and act as intercalating agents, in addition to inhibiting topoisomerase activity. [3]

Aporphine natural products occur with either the (R)- or (S)- isomeric forms, or they can be achiral. Furthermore, morphine-based natural products can be heated in acid to give aporphine degradation products; one example is the FDA-approved Parkinson's drug apomorphine, which was first discovered by the Finnish chemist Adolf Edvard Arppe in 1845. [4]

Aporphines can occur as either (R)- or (S)-isomers, or as achiral compounds, and while many of these are toxic, some have been used for their medicinal value and have been approved by the FDA and world markets. Aporphines.png
Aporphines can occur as either (R)- or (S)-isomers, or as achiral compounds, and while many of these are toxic, some have been used for their medicinal value and have been approved by the FDA and world markets.

Apomorphine

Apomorphine is a derivative of aporphine. The compound is historically obtained by heating morphine with hydrochloric acid. Contrary to its name, apomorphine does not contain morphine or its skeleton, nor does it bind to opioid receptors. The apo- prefix indicates that it is a morphine derivative.

Historically, apomorphine has seen a variety of clinical uses including as a treatment for anxiety and cravings in alcoholics, as an emetic, and more recently in treating erectile dysfunction. It was also used as a private treatment for heroin addiction. Still, there is no clinical evidence that apomorphine is an effective and safe treatment for opiate addiction.

Currently, apomorphine is used in the treatment of Parkinson's disease. It is a potent emetic, typically administered with an antiemetic such as domperidone. Apomorphine is also utilized in veterinary medicine to induce therapeutic emesis in canines that have recently ingested toxic or foreign substances. [5]

Effects

Aporphine is a dopamine receptor agonist targeting the D1 and D2 receptors. [6] In rodents, aporphine administration has been demonstrated to activate gene expression, specifically in the nuclei of the hypothalamus, resulting in stereotypical behavior of erection and yawning. In humans, aporphine produces nonsexual erections that are enhanced by erotic stimulation without changes in libido, but significant side effects can occur. A sublingual formulation of aporphine 2-4 mg with a rapid onset of action has been developed, proven to be efficacious in erectile dysfunction patients with controlled diabetes, hypertension, benign prostatic hypertrophy or coronary vascular disease. [7]

Synthesis

Aporphine and its derivatives can be obtained through various synthetic methods.

Several natural products including semisynthetic analogs belonging to the aporphine class have been synthesized. These include apomorphine by Neumeyer [8] and Raminelli, [9] Pukateine by Happel, [10] Isocorydine by Di, [11] Nuciferine and Oliveroline by Cuny, [12] [13] Glaucine by Meyers, [14] Dicentrine by Cava, [15] and Lysicamine by Raminelli. [16]

Toxicity

Most aporphine alkaloids are toxic and typically exhibit antagonistic effects to dopamine. Many of them have anticonvulsant activity or induce convulsions in animals due to cytotoxic activity. [17]

Some aporphine alkaloids (such as crebanine) have been found to present arrhythmic activity and higher toxicity. In one study, a couple of target derivatives were evaluated for their anti-arrhythmic potential in the mouse model of ventricular fibrillation. Here, preliminary structure-activity/toxicity relationship analyses were carried out. Of these target derivatives, a certain bromo-substituted product of crebanine displayed significant anti-arrhythmic activity and a lower toxicity. In a significant number of rats, this product caused reduction in the incidence of VF, increase in the resumption of sinus rhythm from arrhythmia, and increase in maintaining sinus rhythm. The results from this limited study indicate that this specific aporphine alkaloid could be considered as a promising candidate in the treatment of arrhythmia. [18]

Pharmacology

According to the U.S. Patent & Trademark Office, aporphine derivatives can treat oxidative stress-induced diseases. Specifically, it inhibits lipid peroxidase and performs free radical-scavenging activities, thereby exhibiting a protective effect on endothelial cells. This reduces oxidative stress which may induce diseases such as cardiovascular disease, Alzheimer's disease, kidney disease, diabetes, cancer etc. [19]

Aporphine alkaloids present in Litsea glutinosa, a tropical plant with antioxidant and anti-parasitic properties, are claimed to contribute to anti-cancer activity. Research has illustrated the antiproliferative and cytotoxic effects of aporphine-containing extracts of Litsea glutinosa. [20]

(R)-Aporphine is a dopamine receptor D1 antagonist with a Ki of 717nM [21] and a dopamine receptor D2 antagonist with a Ki of 527nM. [22] Aporphine and its related alkaloids bulbocapnine, boldine, glaucine, and corytuberine are antipsychotic, exert naloxone-reversible antinociceptive activity and, except for corytuberine, are anticonvulsant. [23] Some derivatives of aporphine such as (S)-(+)-N-propylnorapomorphine have potential as low side effect profile antipsychotics. (S)-(+)-N-Propylnorapomorphine is highly selective for meso-limbic dopaminergic tracts and function as efficacious partial agonists, with no elevation in prolactin. [24]

Pharmacokinetics

Aporphine is hydroxylated in the body to form apomorphine. [25]

Psychoactive effects

The Nymphaea species, particularly Nymphaea Caerulea, contains aporphine alkaloids and is utilized in various contexts. [26] Extracts of this plant when ingested or smoken in high doses are reported to produce euphoria and hallucinations. Commonly known as the blue lotus, Nymphaea Caerulea is available in several forms, including dried plant material, teas, and extracts for electronic cigarettes. The psychoactive effects of the flower are attributed to two aporphine alkaloids: apomorphine and nuciferine. These compounds have mixed effects on serotonin and dopamine receptors, functioning as a dopaminergic agonist. [27]

Effects on animals

There are no studies on aporphine in animals. However, studies on subcutaneous apomorphine injection, the bioactive form of aporphine, have been carried out. In a 5-day study, mice were administered up to 10 mg/kg apomorphine subcutaneously daily. No adverse effects were observed other than a slight increase in dopamine levels. [28] Notably, apomorphine is used in veterinary clinics as an emetic due to severe off-target effects that lead to vomiting. [29]

In another study, mice were administered a single 40 mg/kg dose of apomorphine. Slight DNA damage was observed in brain tissue three hours after treatment. [30]

See also

Related Research Articles

<span class="mw-page-title-main">Ergoline</span> Chemical compound

Ergoline is a chemical compound whose structural skeleton is contained in a variety of alkaloids, referred to as ergoline derivatives or ergoline alkaloids. Ergoline alkaloids, one being ergine, were initially characterized in ergot. Some of these are implicated in the condition ergotism, which can take a convulsive form or a gangrenous form. Even so, many ergoline alkaloids have been found to be clinically useful. Annual world production of ergot alkaloids has been estimated at 5,000–8,000 kg of all ergopeptines and 10,000–15,000 kg of lysergic acid, used primarily in the manufacture of semi-synthetic derivatives.

<span class="mw-page-title-main">Epibatidine</span> Toxic chemical from some poison dart frogs

Epibatidine is a chlorinated alkaloid that is secreted by the Ecuadoran frog Epipedobates anthonyi and poison dart frogs from the Ameerega genus. It was discovered by John W. Daly in 1974, but its structure was not fully elucidated until 1992. Whether epibatidine is the first observed example of a chlorinated alkaloid remains controversial, due to challenges in conclusively identifying the compound from the limited samples collected by Daly. By the time that high-resolution spectrometry was used in 1991, there remained less than one milligram of extract from Daly's samples, raising concerns about possible contamination. Samples from other batches of the same species of frog failed to yield epibatidine.

<span class="mw-page-title-main">Apomorphine</span> Chemical compound

Apomorphine, sold under the brand name Apokyn among others, is a type of aporphine having activity as a non-selective dopamine agonist which activates both D2-like and, to a much lesser extent, D1-like receptors. It also acts as an antagonist of 5-HT2 and α-adrenergic receptors with high affinity. The compound is historically a morphine decomposition product made by boiling morphine with concentrated acid, hence the -morphine suffix. Contrary to its name, apomorphine does not actually contain morphine or its skeleton, nor does it bind to opioid receptors. The apo- prefix relates to it being a morphine derivative ("[comes] from morphine").

<span class="mw-page-title-main">Dopamine agonist</span> Compound that activates dopamine receptors

A dopamine agonist is a compound that activates dopamine receptors. There are two families of dopamine receptors, D1-like and D2-like. They are all G protein-coupled receptors. D1- and D5-receptors belong to the D1-like family and the D2-like family includes D2, D3 and D4 receptors. Dopamine agonists are primarily used in the treatment of the motor symptoms of Parkinson's disease, and to a lesser extent, in hyperprolactinemia and restless legs syndrome. They are also used off-label in the treatment of clinical depression. Impulse control disorders are associated with the use of dopamine agonists for whatever condition.

<span class="mw-page-title-main">WIN-35428</span> Chemical compound

WIN 35,428 is a stimulant drug used in scientific research. CFT is a phenyltropane based dopamine reuptake inhibitor and is structurally derived from cocaine. It is around 3-10x more potent than cocaine and lasts around 7 times longer based on animal studies. While the naphthalenedisulfonate salt is the most commonly used form in scientific research due to its high solubility in water, the free base and hydrochloride salts are known compounds and can also be produced. The tartrate is another salt form that is reported.

<span class="mw-page-title-main">18-Methoxycoronaridine</span> Chemical compound

18-Methoxycoronaridine, also known as zolunicant, is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemists Upul K. Bandarage and Martin E. Kuehne from the University of Vermont. In animal studies it has proven to be effective at reducing self-administration of morphine, cocaine, methamphetamine, nicotine and sucrose. It has also been shown to produce anorectic effects in obese rats, most likely due to the same actions on the reward system which underlie its anti-addictive effects against drug addiction.

<span class="mw-page-title-main">Troparil</span> Chemical compound

Troparil is a stimulant drug used in scientific research. Troparil is a phenyltropane-based dopamine reuptake inhibitor (DRI) that is derived from methylecgonidine. Troparil is a few times more potent than cocaine as a dopamine reuptake inhibitor, but is less potent as a serotonin reuptake inhibitor, and has a duration spanning a few times longer, since the phenyl ring is directly connected to the tropane ring through a non-hydrolyzable carbon-carbon bond. The lack of an ester linkage removes the local anesthetic action from the drug, so troparil is a pure stimulant. This change in activity also makes troparil slightly less cardiotoxic than cocaine. The most commonly used form of troparil is the tartrate salt, but the hydrochloride and naphthalenedisulfonate salts are also available, as well as the free base.

<span class="mw-page-title-main">Nuciferine</span> Chemical compound

Nuciferine is an alkaloid found within the plants Nymphaea caerulea and Nelumbo nucifera.

Dopamine receptor D<sub>3</sub> Subtype of Dopamine Receptor

Dopamine receptor D3 is a protein that in humans is encoded by the DRD3 gene.

<span class="mw-page-title-main">Propylnorapomorphine</span> Chemical compound

N-n-Propylnorapomorphine (NPA) is an aporphine derivative dopamine agonist closely related to apomorphine. In rodents it has been shown to produce hyperactivity, stereotypy, hypothermia, antinociception, and penile erection, among other effects. Notably, its effects on locomotion are biphasic, with low doses producing inhibition and catalepsy and high doses resulting in enhancement of activity. This is likely due to preferential activation of D2/D3 autoreceptors versus postsynaptic receptors, the latter of which overcomes the former to increase postsynaptic dopaminergic signaling only with high doses.

<span class="mw-page-title-main">Epiboxidine</span> Chemical compound

Epiboxidine is a chemical compound which acts as a partial agonist at neural nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes. It was developed as a less toxic analogue of the potent frog-derived alkaloid epibatidine, which is around 200 times stronger than morphine as an analgesic but produces extremely dangerous toxic nicotinic side effects.

<span class="mw-page-title-main">Glaucine</span> Chemical compound

Glaucine(1,2,9,10-TetraMethoxyAporphine, Bromcholitin, Glauvent, Tusidil, Tussiglaucin) is an aporphine alkaloid found in several different plant species in the family Papaveraceae such as Glaucium flavum, Glaucium oxylobum and Corydalis yanhusuo, and in other plants like Croton lechleri in the family Euphorbiaceae.

<span class="mw-page-title-main">Tetrahydropalmatine</span> Isoquinoline alkaloid, found mainly in Corydalis

Tetrahydropalmatine (THP) is an isoquinoline alkaloid found in several different plant species, mainly in the genus Corydalis, but also in other plants such as Stephania rotunda. These plants have traditional uses in Chinese herbal medicine. The pharmaceutical industry has synthetically produced the more potent enantiomer Levo-tetrahydropalmatine (Levo-THP), which has been marketed worldwide under different brand names as an alternative to anxiolytic and sedative drugs of the benzodiazepine group and analgesics such as opiates. It is also sold as a dietary supplement.

<span class="mw-page-title-main">Stepholidine</span> Chemical compound

(−)-Stepholidine is a protoberberine alkaloid found in the plant Stephania intermedia.

<span class="mw-page-title-main">Arylcyclohexylamine</span> Class of chemical compounds

Arylcyclohexylamines, also known as arylcyclohexamines or arylcyclohexanamines, are a chemical class of pharmaceutical, designer, and experimental drugs.

<span class="mw-page-title-main">Tabernanthine</span> Chemical compound

Tabernanthine is an alkaloid found in Tabernanthe iboga.

<span class="mw-page-title-main">Sonepiprazole</span> Chemical compound

Sonepiprazole (U-101,387, PNU-101,387-G) is a drug of the phenylpiperazine class which acts as a highly selective D4 receptor antagonist. In animals, unlike D2 receptor antagonists like haloperidol, sonepiprazole does not block the behavioral effects of amphetamine or apomorphine, does not alter spontaneous locomotor activity on its own, and lacks extrapyramidal and neuroendocrine effects. However, it does reverse the prepulse inhibition deficits induced by apomorphine, and has also been shown to enhance cortical activity and inhibit stress-induced cognitive impairment. As a result, it was investigated as an antipsychotic for the treatment of schizophrenia in a placebo-controlled clinical trial, but in contrast to its comparator olanzapine no benefits were found and it was not researched further for this indication.

<span class="mw-page-title-main">SB-206553</span> Chemical compound

SB-206553 is a drug which acts as a mixed antagonist for the 5-HT2B and 5-HT2C serotonin receptors. It has anxiolytic properties in animal studies and interacts with a range of other drugs. It has also been shown to act as a positive allosteric modulator of α7 nicotinic acetylcholine receptors. Modified derivatives of SB-206553 have been used to probe the structure of the 5-HT2B receptor.

Iboga-type alkaloids are a set of monoterpene indole alkaloids comprising naturally occurring compounds found in Tabernanthe and Tabernaemontana, as well as synthetic structural analogs. Naturally occurring iboga-type alkaloids include ibogamine, ibogaine, tabernanthine, and other substituted ibogamines. Many iboga-type alkaloids display biological activities such as cardiac toxicity and psychoactive effects, and some have been studied as potential treatments for drug addiction.

<span class="mw-page-title-main">Aporphine alkaloids</span>

Aporphine alkaloids are naturally occurring chemical compounds from the group of alkaloids. After the benzylisoquinoline alkaloids they are the second largest group of isoquinoline alkaloids.

References

  1. Stévigny C, Bailly C, Quetin-Leclercq J (March 2005). "Cytotoxic and antitumor potentialities of aporphinoid alkaloids". Current Medicinal Chemistry. Anti-Cancer Agents. 5 (2): 173–182. doi:10.2174/1568011053174864. hdl:2078.1/10136. PMID   15777224.
  2. Oliver-Bever B (January 1983). "Medicinal plants in tropical West Africa. II. Plants acting on the nervous system". Journal of Ethnopharmacology. 7 (1): 1–93. doi:10.1016/0378-8741(83)90082-X. PMID   6132025.
  3. Hoet S, Stévigny C, Block S, Opperdoes F, Colson P, Baldeyrou B, et al. (May 2004). "Alkaloids from Cassytha filiformis and related aporphines: antitrypanosomal activity, cytotoxicity, and interaction with DNA and topoisomerases". Planta Medica. 70 (5): 407–413. doi:10.1055/s-2004-818967. PMID   15124084.
  4. Auffret M, Drapier S, Vérin M (June 2018). "The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future". Drugs in R&D. 18 (2): 91–107. doi:10.1007/s40268-018-0230-3. PMC   5995787 . PMID   29546602.
  5. Guardia J, Casas M, Prat G, Trujols J, Segura L, Sánchez-Turet M (October 2002). "The apomorphine test: a biological marker for heroin dependence disorder?". Addiction Biology. 7 (4): 421–426. doi:10.1080/1355621021000006206. PMID   14578019. S2CID   32386793.
  6. Goldman ME, Kebabian JW (January 1984). "Aporphine enantiomers. Interactions with D-1 and D-2 dopamine receptors". Molecular Pharmacology. 25 (1): 18–23. PMID   6231468.
  7. Anastasiadis AG, Droggin D, Davis AR, Salomon L, Shabsigh R (January 2004). "Male and Female Sexual Dysfunction: Epidemiology, Pathophysiology, Classifications, and Treatment.". Principles of Gender-Specific Medicine: Aporphine SL. Academic Press. pp. 573–585. doi:10.1016/B978-012440905-7/50321-2. ISBN   978-0-12-440905-7.
  8. Neumeyer JL, Neustadt BR, Oh KH, Weinhardt KK, Boyce CB, Rosenberg FJ, Teiger DG (November 1973). "Aporphines. 8. Total synthesis and pharmacological evaluation of (plus or minus)-apomorphine, (plus or minus)-apocodeine, (plus or minus)-N-n-propylnorapomorphine, and (plus or minus)-N-n-propylnorapocodeine". Journal of Medicinal Chemistry. 16 (11): 1223–1228. doi:10.1021/jm00269a601. PMID   4201182.
  9. Muraca AC, Perecim GP, Rodrigues A, Raminelli C (2017-06-20). "Convergent Total Synthesis of (±)-Apomorphine via Benzyne Chemistry: Insights into the Mechanisms Involved in the Key Step". Synthesis. 49 (16): 3546–3557. doi:10.1055/s-0036-1588855. ISSN   0039-7881.
  10. Zymalkowski F, Happel KH (September 1969). "[The total synthesis of (plus minus)-pukatein]". Chemische Berichte. 102 (9): 2959–2966. doi:10.1002/cber.19691020910. PMID   5806148.
  11. Zhong M, Jiang Y, Chen Y, Yan Q, Liu J, Di D (2015-11-01). "Asymmetric total synthesis of (S)-isocorydine". Tetrahedron: Asymmetry. 26 (20): 1145–1149. doi:10.1016/j.tetasy.2015.09.008. ISSN   0957-4166.
  12. Cuny GD (2004-02-10). "Intramolecular ortho-Arylation of Phenols Utilized in the Synthesis of the Aporphine Alkaloids (.+-.)-Lirinidine and (.+-.)-Nuciferine". ChemInform. 35 (6). doi:10.1002/chin.200406170. ISSN   0931-7597.
  13. Ku AF, Cuny GD (March 2015). "Synthetic studies of 7-oxygenated aporphine alkaloids: preparation of (-)-oliveroline, (-)-nornuciferidine, and derivatives". Organic Letters. 17 (5): 1134–1137. doi:10.1021/acs.orglett.5b00007. PMID   25710592.
  14. Gottlieb L, Meyers AI (October 1990). "An asymmetric synthesis of aporphine and related alkaloids via chiral formamidines. (+)-glaucine, (+)-homoglaucine, and (-)-8,9-didemethoxythalisopavine". The Journal of Organic Chemistry. 55 (21): 5659–5662. doi:10.1021/jo00308a029. ISSN   0022-3263.
  15. Cava MP, Stern P, Wakisaka K (1973-01-01). "An improved photochemical aporphine synthesis: New syntheses of dicentrine and cassameridine". Tetrahedron. 29 (15): 2245–2249. doi:10.1016/S0040-4020(01)93344-7. ISSN   0040-4020.
  16. Rossini AF, Muraca AC, Casagrande GA, Raminelli C (October 2015). "Total Syntheses of Aporphine Alkaloids via Benzyne Chemistry: An Approach to the Formation of Aporphine Cores". The Journal of Organic Chemistry. 80 (20): 10033–10040. doi:10.1021/acs.joc.5b01634. PMID   26375603.
  17. Wu YC (2006). "New research and development on the Formosan Annonaceous plants. Aporphinoids". Studies in natural products chemistry. Elsevier. pp. 957–1023.
  18. US EPA National Center for Environmental Assessment (2009-03-15). "Synthesis and Structure-Activity Relationships of a Series of Aporphine Derivatives with Antiarrhythmic Activities and Acute Toxicity". hero.epa.gov. Retrieved 2022-03-17.
  19. "Broad US patent issued to Dyadic International". Focus on Catalysts. 2012 (11): 7. November 2012. doi:10.1016/s1351-4180(12)70458-0. ISSN   1351-4180.
  20. Chawra HS, Gupta G, Singh SK, Pathak S, Rawat S, Mishra A, Gilhotra RM (2021-11-30). "Phytochemical constituents, Ethno medicinal properties and Applications of Plant: Litsea glutinosa (Lour.) C.B. Robinson (Lauraceae)". Research Journal of Pharmacy and Technology: 6113–6118. doi:10.52711/0974-360x.2021.01062. ISSN   0974-360X.
  21. Hedberg MH, Linnanen T, Jansen JM, Nordvall G, Hjorth S, Unelius L, Johansson AM (August 1996). "11-substituted (R)-aporphines: synthesis, pharmacology, and modeling of D2A and 5-HT1A receptor interactions". Journal of Medicinal Chemistry. 39 (18): 3503–3513. doi:10.1021/jm960189i. PMID   8784448.
  22. Linnanen T, Brisander M, Unelius L, Rosqvist S, Nordvall G, Hacksell U, Johansson AM (April 2001). "Atropisomeric derivatives of 2',6'-disubstituted (R)-11-phenylaporphine: selective serotonin 5-HT(7) receptor antagonists". Journal of Medicinal Chemistry. 44 (9): 1337–1340. doi:10.1021/jm0108505. PMID   11311055.
  23. Zetler G (1988). "Neuroleptic-like, anticonvulsant and antinociceptive effects of aporphine alkaloids: bulbocapnine, corytuberine, boldine and glaucine". Archives Internationales de Pharmacodynamie et de Therapie. 296: 255–281. PMID   2907279.
  24. Baldessarini RJ, Campbell A, Ben-Jonathan N, Ellingboe J, Zong R, Neumeyer JL (August 1994). "Effects of aporphine isomers on rat prolactin". Neuroscience Letters. 176 (2): 269–271. doi:10.1016/0304-3940(94)90098-1. PMID   7830962. S2CID   38264784.
  25. Bertol E, Fineschi V, Karch SB, Mari F, Riezzo I (February 2004). "Nymphaea cults in ancient Egypt and the New World: a lesson in empirical pharmacology". Journal of the Royal Society of Medicine. 97 (2): 84–85. doi:10.1177/014107680409700214. PMC   1079300 . PMID   14749409.
  26. Seligman, Sian (2023-01-13). "Blue Lotus Flower: Smoking, Tea & More". DoubleBlind Mag. Retrieved 2023-01-19.
  27. Schimpf M, Ulmer T, Hiller H, Barbuto AF (August 2021). "Toxicity From Blue Lotus (Nymphaea caerulea) After Ingestion or Inhalation: A Case Series". Military Medicine. 188 (7–8): e2689–e2692. doi: 10.1093/milmed/usab328 . PMID   34345890.
  28. Grünblatt E, Mandel S, Berkuzki T, Youdim MB (July 1999). "Apomorphine protects against MPTP-induced neurotoxicity in mice". Movement Disorders. 14 (4): 612–618. doi:10.1002/1531-8257(199907)14:4<612::aid-mds1010>3.0.co;2-6. PMID   10435498.
  29. Scott KA, Qureshi MH, Cox PB, Marshall CM, Bellaire BC, Wilcox M, et al. (December 2020). "A Structural Analysis of the FDA Green Book-Approved Veterinary Drugs and Roles in Human Medicine". Journal of Medicinal Chemistry. 63 (24): 15449–15482. doi:10.1021/acs.jmedchem.0c01502. PMID   33125236. S2CID   226218045.
  30. Picada JN, Flores DG, Zettler CG, Marroni NP, Roesler R, Henriques JA (May 2003). "DNA damage in brain cells of mice treated with an oxidized form of apomorphine". Brain Research. Molecular Brain Research. 114 (1): 80–85. doi:10.1016/s0169-328x(03)00127-x. PMID   12782396.